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Primary cultures of hepatocytes are powerful models in studying the sequence of events that are necessary for cell progression
from a G0-like state to S phase. The models mimic the physiological process of hepatic regeneration after liver injury or
partial hepatectomy. Many reports suggest that the mitogen-activated protein kinase (MAPK) ERK1/2 can support hepatocyte
proliferation in vitro and in vivo and the MEK/ERK cascade acts as an essential element in hepatocyte responses induced by the
EGF. Moreover, its disregulation has been associated with the promotion of tumor cell growth of a variety of tumors, including
hepatocellular carcinoma. Whereas the strict speciﬁcity of action of ERK1 and ERK2 is still debated, the MAPKs may have
speciﬁc biological functions under certain contexts and according to the differentiation status of the cells, notably hepatocytes.
In this paper, we will focus on MEK1/2-ERK1/2 activations and roles in normal rodent hepatocytes in vitro and in vivo after
partial hepatectomy and in human hepatocarcinoma cells. The possible speciﬁcity of ERK1 and ERK2 in normal and transformed
hepatocyte will be discussed in regard to other differentiated and undifferentiated cellular models.
1. Introduction
Adult hepatocyte has a long lasting life and rarely divides
in normal conditions. However, under certain situations of
stress as viral infection, toxic injury, and partial hepatectomy,
they can divide in reaction to the loss of liver mass. Among
these different situations, the regeneration of liver after
partial hepatectomy (PHT) provides an in vivo model to
dissect the mechanisms of control of a highly differentiated
normal cell growth. Indeed, surgical removal of 70% of
the liver synchronized most hepatocytes and the cell cycle
is characterized by a fast G0/G1 phase transition of the
cell cycle after PHT, followed by a well-synchronized long
G1 phase [1–3]. There is an initial step priming phase, in
which the activation of IL6 and TNF alpha pathways allows
hepatocytes to undergo the transition from G0 to G1 in
vivo leading to activation of NF-kB, AP-1, and STAT3. Then,
hepatocytes proliferation is regulated by different mitogens
including HGF, IGF1, ligands of the EGF, and FGF receptors
[4, 5]. In vitro, hepatocytes can also proliferate after growth
factor stimulations and in vitro rat hepatocyte cell cycle
progression highly mimicked the kinetic of cell proliferation
during liver regeneration after PHT [6, 7]. In response to
mitogens (i.e., EGF, HGF, PDGF, TGF alpha), hepatocytes
maintained in short-term culture can undergo one or two
rounds of replication (for reviews see [4, 8, 9]). This model
has been extensively used by many laboratories illustrating
that primary culture of hepatocytes can be a powerful model
to study the precise sequences of events which are necessary
for hepatocyte cell cycle progression from a G0-like state to S
phase.
There are four MAPK families categorized by sequence
homology and functions: ERK1/2, p38, JNK, and ERK5.
Mostly, JNK and p38 are more activated in response to
cellular stress and cytokines. Numerous studies have shown
that growth factor could enhance cell proliferation and
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survival through the activation of the MEK1/2-ERK1/2
pathway, including hepatocytes in primary culture. Indeed,
the ERK1/2 are activated in response to external and internal
stimuli in numerous cell types and play a central role inmany
signal transduction pathways. The Ras-Raf-MEK1/2-ERK1/2
pathway couples signal from the cell surface receptors to
cytoplasmic substrates and transcription factors, which reg-
ulate gene expression [10–12]. Following binding of growth
factors, cytokines, or extracellular matrix proteins to their
receptors, activation of the cascade can occur. The pathway
involves the activation of the MEK1/2, by c-Raf which in
turn, activates ERK1/2. ERK1/2 can directly phosphorylate
many targets (over 160) including transcription factors (e.g.,
Ets-1, c-Jun, c-Myc, P53) which leads to the induction
of many cell cycle proteins (e.g., p21, Cyclin D1, cdk1).
ERK1/2 can also phosphorylate and activate cytoplasmic
substrates like the 90KDa ribosomal S6 kinase (P90 RSK)
which leads to the activation of the CREB transcription
factor, apoptotic factors (e.g., caspase 9, bad, Bim), and also
contribute to a mechanism of retrocontrol of the cascade
by phosphorylation of the EGFr, Sos, and Raf. In addition
to proliferation, the Ras-Raf-MEK1/2-ERK1/2 cascade can
antagonize cell death and activate survival signals. Aberrant
activation of this pathway is frequently observed in human
HCC [13–16]. The MEK-ERK pathway has been implicated
in the regulation of both G1/S and G2/M transitions and
mitosis in somatic cells. Whereas the possible speciﬁcity
of MEK1 and 2, ERK1 and 2 isoforms are still in debate,
and disruption of ERK2 leads to embryonic lethality early
in mouse development after the implantation stage [17].
Conversely, ERK1 Knockout mice are viable and fertile [18],
arguing for possible different roles of each kinase or/and that
ERK gene dosage is essential and could drive their apparent
biological differences.
2. Mechanisms in the Sequential
Control of Cell Morphology and G1 Phase
Progression Involve MEK-ERK Activations in
Normal Hepatocytes
There is an agreement that during liver regeneration,
JNK activation is an early event [19] while activation of
ERK1/2 occurs in early and mid-late G1. P38 is present in
normal liver and rapidly inactivated after PHT suggesting
a permissive role in DNA replication [20]. These last ten
years, our laboratory has studied the role of the MEK1/2-
ERK1/2 pathway in the regulation of the cell cycle and
survival of hepatocytes stimulated by the EGF. We looked at
long-term survival, control of multiple cell cycles, apoptosis
engagement of normal rodent hepatocytes, and rat and
human hepatocarcinoma cell lines, in vitro and in vivo.
The MEK1/2-ERK1/2 cascade is activated at two points
of the G1 progression in mature rat hepatocytes [21]: the
ﬁrst one occurs in early G1 after PHT; the second one
occurs in mid-late G1 phase and is associated with the
induction of cyclin D1 [22], a cyclin associated to late
G1 phase progression of many cells including hepatocytes
[23, 24]. In vitro, during tissue disruption by collagenase,
hepatocytes can enter into the G1 phase and undergo,
depending on the culture conditions in primary culture,
at least one round of division [6, 7, 25]. In the absence
of growth factor, rat hepatocytes are blocked at 2/3 of
G1 phase and rapidly progress through apoptosis [26, 27].
The growth factor (i.e., EGF) is a morphogen in early G1
phase by inducing controlled spreading of hepatocytes via
a MEK/ERK-integrin β1 regulation, in vitro [28]. During
hepatocyte spreading, Rac1 trough NADPH oxidase is part
of the signalling pathway constituted by FAK-Rac1-ERK
that regulates focal adhesion disassembly important for
the turnover of adhesion sites that leads to cell spread
[29]. The growth factor-induced nuclear translocation of
ERK is an adhesion-dependent event and requires signalling
from Rac1 [30]. Cell spread and migration are dynamic
processes involving the focal adhesion assembly/disassembly
and ERK1/2 are activated downstream of FAK while ERK1/2
can mediate its phosphorylation [31].
A mitogenic effect occurs in mid-late G1 phase and
allows hepatocytes to progress through a growth factor
restriction point at two thirds of the G1 phase [32]. MEK
signaling cascade is essential for progression to late G1 phase
in vitro as well as in vivo after PHT [21]. Indeed, a growth
factor-MEK dependency could be deﬁned in mid-late G1
phase in regenerating liver between 9 and 12 h after PHT.
This activation controls expression of cyclin D1 and cdk1
which are upregulated in the prereplicative phase of liver
regeneration and in proliferating hepatocytes in vitro. Very
interesting results from the Hansen’s lab have demonstrated
that adhesion to polymerized collagen could induce growth
arrest by inhibiting the Ras/ERK pathway to cyclin D1
required in late G1 [33, 34].Moreover, the involvement of the
cell shape/motility via an ERK-MLCK-P70S6K-dependent
regulation of G1/S was speciﬁed in proliferating hepatocytes
[35] and in other cell types [31, 36, 37]. All these results
highlight the mechanisms by which a growth factor can tem-
porally control morphogenic and mitogenic signals during
G1 phase progression (see Scheme 1). A precise location
in the cell cycle appears determinant for the regulation
of ERK1/2 pathway and sequential checkpoints in early
G1, mid-late G1, and G1/S transition control hepatocyte
cell cycle progression, making them permissive for DNA
replication.
The signaling crosstalk is an important aspect of the
regulation of liver regeneration and other pathways (i.e.,
HGF/c-MET, IGF1/IGF-R, GH) are activated and required
for efficient liver regeneration. Indeed, GH receptor KO
impaired regeneration with a downregulation of ERK1/2
activation [38]. Liver regeneration and ERK pathway are
also impaired in mice with liver-speciﬁc knockouts of IGF-
1R or IGF binding protein 1 [39, 40]. HGF and IGF-1
strongly activated AKT and ERK1/2 in vitro [41]. In vivo,
EGF and HGF have been implicated in liver regeneration,
but speciﬁc deletion of EGF receptor in hepatocyte led to
liver regeneration deﬁciencies after 2/3 PHT in mice without
activation defect of ERK1/2 while p38 MAPK and NF-
kB activation was reduced in regenerating mutant livers,
indicating an impaired stress response after hepatectomy
[42]. Indeed, p38 MAPK could play a permissive role in
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Scheme 1: In vivo and in vitroMEK1/2-ERK1/2 dependencies during G1 phase progression.
DNA replication during liver regeneration consistent with
a role in the maintenance of hepatocyte cell cycle arrest
in adult liver [20], while JNK could be involved in the
G0/G1 transition [19]. Interestingly, hepatocyte deletion of
c-Met which led to liver regeneration defect was associated
with MEK-ERK pathway inhibition highlighting that HGF
contributes dominantly to ERK1/2 activation in vivo [43, 44].
A persistent EGF supplementation in vitro only partially
rescues the effect of ERK1/2 downregulation in c-MET
depleted hepatocytes and restores to some extent DNA
synthesis and protein levels of cdk1, Aurora A and B, and
Mad2 [44].
3. Transient Blockade of theMEK/ERK Pathway
Using AllowsMultiple Cell Cycles
Different in vitro models have previously described that
hepatocytes can undergo several cell cycles in primary
cultures and long-term survival when appropriate culture
conditions are provided [45–52]. Indeed, removal of EGF
in long-term survival DMSO culture conditions followed by
readdition of the growth factor was accompanied with an
increase in DNA synthesis, and multiple round of replication
could be observed by alternating addition/removal [53–
55]. In coculture with liver biliary cell [56–60], EGF alone
prolonged cell progression up to late G1 phase, whereas
TNFα mediated extracellular remodeling is required for
multiple division cycles [51]. Interestingly, TNFα promoted
an extracellular matrix degradation required for initiating a
new hepatocyte division wave. Furthermore, a network of
ECM or polymerized collagen type I gel induces a highly
differentiated but growth-arrested phenotype in primary
cultures, whereas a ﬁlm of collagen promotes cell cycle
progression and dedifferentiation [34, 61, 62]. Hepatocytes
dedifferentiation is reversible in consequence of a speciﬁc
network triggered by the extracellular matrix, an active
process driven by FAK-mediated AKT and ERK1/2 signaling
[63]. As well, in hepatocellular carcinoma cells, increasing
matrix stiffness promotes proliferation whereas soft environ-
ment induces cellular dormancy [64].
All these experiments and others indicated that adult
hepatocytes could undergo long-term survival and multiple
cell divisions. In this context, our group have demonstrated
that rat hepatocytes seeded in the presence of EGF (in the
absence of FCS) increased cell spreading [28] and greatly
enhanced cell survival [65]. However, only one peak of
BrdU incorporation was obtained in EGF-seeded cultured
whereas nearly 100% of the hepatocytes accomplished a
complete cell cycle. Time-lapse cinematography showed that
both mononuclear and binuclear hepatocytes underwent
mitosis [66]. Some reports have suggested that sustained
activation of ERK inhibits hepatocyte DNA replication and
that transient activations of this pathway could stimulate
DNA synthesis [67, 68]. We therefore hypothesized that
maintained MEK1/2-ERK1/2 stimulation of hepatocytes by
EGF could lead to a sustained activation of ERK responsible
for the negative control of the progression in a second cell
cycle. Indeed, when the MEK/ERK pathway is transiently
inhibited with the MEK inhibitor U0126 about 60% of
hepatocytes did replicate their DNA showing that primary
hepatocytes are able to perform 2 cell cycles when a break
of the MEK/ERK signalling pathway activity is done [66].
In addition, cyclin D1, E, A2, cdk1, P21, and P27 were
downregulated in MEK-inhibited cells and induced after the
U0126 removal. A third peak of DNA synthesis in EGF-
seeded hepatocytes by performing another 2 days-break of
MEK1/2-ERK1/2 activity could be obtained demonstrating
that EGF-seeded hepatocytes were able to perform multiple
division waves after sequential MEK1/2-ERK1/2 pathway
inhibitions (see Scheme 2).
4. Early Sustained EGF Stimulation and
MEK Inhibition Maintain Hepatocytes in a
Long-Term Survival and Differentiated States
In hepatocytes, in addition to its proliferating properties,
EGF could induce survival. In vitro, in the absence of serum
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Scheme 2: Long-term survival/differentiation in EGF stimulated cells and sequential MEK/ERK inhibitions allowing multiple divisions
waves. Hepatocytes are cultured in presence or absence (-GF) of EGF and after one week of culture, transient inhibitions of MEK/ERK by
U0126 allow EGF-cultured hepatocytes to re-enter in new cell cycles.
and growth factor stimulation, hepatocytes in primary cul-
ture adhered to the plastic support but underwent spreading
with a very low efficiency and die as observed by rapid
caspase3/7 activations evaluated using a DEVD-AMC assay
[65]. At the opposite, hepatocytes seeded with EGF alone
and cultured with the growth factor all along the culture
time present a high level of differentiation. Cell survival
can be maintained at least 15 to 20 days in this culture
condition. Albumin expression reached a level closed to half
of freshly isolated cells, and CYP450s can be induced by
3MC or PB showing that the detoxiﬁcation machinery is
still fully operative. In these cells, ERK localization could
be determinant for the cell phenotype since Rosseland et al.
showed that the cytoplasmic retention of transient peroxide-
activated ERK provides survival in primary cultures of rat
hepatocytes [69]. Indeed, MEK1 and MEK2 could regulate
distinct functions by sorting ERK2 to different intracellular
compartments in response to growth factor and ERK2
intracellular localization could determine whether growth
factors mediate hepatocyte proliferation or survival in an
adhesion-dependent manner [70–72].
Surprisingly, an improvement of the survival of hepato-
cytes continuously treated with the MEK inhibitor U0126
can be obtained [65]. Indeed, a permanent treatment with
U0126 keeps hepatocytes for more than 2 weeks in survival.
All the genes of detoxiﬁcation analyzed (Cyp 1A1, 1A2, 2B2,
3A23, and GSTa2) as well as the aldolase B gene are induced
all along the period of treatment. U0126 removal from the
culture medium is accompanied with a fast decrease of the
expression of these markers related to the reentry of the cells
in a new cycle.
In summary, early and sustained EGF stimulation, in the
absence of serum, could be a good compromise between
“classical monolayers” with limited survival/differentiation,
and long-term sophisticated and labor intensive cultures.
This model emphasizes that early EGF stimulation of
hepatocytes in the absence of FCS and transient or sustained
inhibition of the MEK/ERK pathway represent serum-free
models (Scheme 2) that will be very helpful for pharmaco-
logical studies on drug metabolism and toxicity.
5. Speciﬁcity of theMAPK ERK1 and
ERK2 Signaling: ERK2 Controls S Phase
ERK2 Entry whereas ERK1 Regulates
Survival in Hepatocyte
The strict speciﬁcity of action of the MAPKs is still debated
and today, no one can affirm with certitude the full
redundancy of ERK1 and ERK2 or at the contrary the
speciﬁcity of action of each protein. On one hand, the simple
observation of the phenotypes of knockout animals for
ERK1 and ERK2 fuels the idea that each ERK isoform could
regulate speciﬁc and non overlapping functions. Invalidating
ERK1 has no strong and lethal impact on animals: mice
are viable, fertile, and of normal size [18]. Actually, only
a few defects affecting different cell lineages have been
related. Thereby, ERK1 was associated with maturation of
thymocytes [18], development of adipose tissue [73], or
osteoclast formation and differentiation [74, 75]. ERK2
knockout is much more severe as embryos die very early
during development [17, 76], because of major defects in
the establishment of extraembryonic tissues [17, 76, 77]. To
counteract this embryonic lethality and ascertain the roles
of ERK2 in embryo or adult tissues, conditional expressions
have been used allowing the invalidation of ERK2 in speciﬁc
sites. Invalidation of Erk2 gene in the neural crest induces
craniofacial and cardiac defects [78]. ERK2 also regulates
multiple stages of T-cells development [79, 80]. Invalidation
of ERK2 in the central neural system (CNS) leads to
anomalies in multiple aspects of social behaviors, decreased
anxiety-related attitude, and impaired long-term memory
[81]. ERK2 also protects the myocardium from ischemia-
reperfusion injury in vivo as Erk2+/− gene-targeted mice
showed enhanced infarction areas [82]. Based on the strict
observation of these phenotypes, one could easily conclude
that ERK1 and ERK2 regulate speciﬁc functions.
Indeed, studies performed on animal and which attri-
buted to ERK1 or ERK2 unique functions did not really
took into account the expression level of each isoform in
the tissues or cell types analyzed. In other words, the
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lethality of ERK2 embryos could reﬂect a speciﬁc role of the
isoform in the establishment of extraembryonic tissues or
could be due to a higher expression of the ERK2 isoform
(compared to ERK1) in these tissues. We must be careful
when drawing some conclusions about speciﬁc roles for
ERK1 and ERK2. Besides, on a purely biochemical point
of view, it has been difficult to associate ERK1 or ERK2
to cellular speciﬁc functions. They share a 84% homology
at the protein level, seem to be activated in response
to similar stimuli and to date no speciﬁc substrate for
each kinase has been characterized. Actually, only a few
papers have reported biochemical differences between both
proteins. Thus, preferential activation of ERK1 versus ERK2
was reported in NFB4 cells after LPA stimulation [83].
At the contrary, activation of ERK2 rather than ERK1
occurs during thrombin-stimulated platelet activation [84].
Another biochemical difference concerns the identiﬁcation
of a speciﬁc scaffolding protein of ERK1 called MP1 (MEK
partner 1). This protein interacts exclusively with MEK1 and
ERK1 at the surface of late endosome [85, 86]. Finally, despite
the fact that both kinases are simultaneously expressed in
all cell types and tissues analyzed, the ERK1 : ERK2 ratio is
quite variable. One of the best examples that illustrates this
is the quite heterogenous expression proﬁle of ERK1 and
ERK2 mRNA in brain [87]. These are essentially the more
pronounced biochemical differences that have been reported
until today and ﬁnally ERK1 and ERK2 appear as tightly close
enzymes.
Interestingly, ERK is highly activated in ectoplacental
cone and extraembryonic ectoderm, which both give rise to
these extraembryonic tissues [88]. Even if the elevated ERK
activity in these tissues has not been attributed to ERK1 or
ERK2, it is likely to be mainly carried by ERK2 isoform,
which would explain the phenotype of ERK2 knockout. It
is indeed assumed that ERK2 is more expressed than ERK1
in nearly all tissues examined so far and, as a consequence
invalidation of ERK2, is supposed to have a stronger impact
on the global ERK activity compared to ERK1 knockout.
Actually, the only one way to compare the expression levels
of ERK1 and ERK2 in cells is the use of a phosphospeciﬁc
antibody, which recognizes the phosphorylation of activation
loop residues Thr202/Tyr204 and Thr185/Tyr187 of ERK1
and ERK2, respectively. This motif is recognized with the
same affinity by the antibody. In a recent report, Leﬂoch et al.
have established a clear correlation between the expression
ratio of ERK1 and ERK2 and their activation ratio [89]. In
this work, the authors have demonstrated that ERK1 and
ERK2 are fully redundant kinases regarding the regulation
of cell proliferation in NIH3T3 cells. A similar observation
was done on embryonic ﬁbroblast genetically deﬁcient for
ERK1 and/or ERK2 [90]. In this study, a strong correlation
was drawn between the quantity of ERK proteins inside the
cell and the intensity of proliferation.
In addition to these works based on the use of genetically
deﬁcient animals and riding the wave following RNAi
discovery, a sustained number of studies have emerged in
the literature in order to decipher the roles of ERK1 and
ERK2. In skeletal myoblasts, proliferation requires one of the
two isoforms, whatever it is, but terminal differentiation is
strictly dependent on ERK2 [91]. According to Liu et al.,
if ERK1 and ERK2 silencing would both affect cell prolif-
eration, each kinase would be involved at different phases
of the cell cycle: ERK1 would regulate G2/M transition
while ERK2 could be essential in G1 phase [92]. A recent
study done by John Blenis’ group has shown that the ERK2
isoform induces epithelial-to-mesenchymal transformation
when overexpressed [93]. Interestingly, ERK1 is not able to
reach the same effect despite high expression levels.
What about the roles of ERK1 and ERK2 in the physiol-
ogy of normal hepatocytes? Interestingly, contrary to other
cell types in which ERK2 is much more expressed compared
to ERK1, normal hepatocytes harbor closely similar levels of
ERK1 and ERK2, according to P-ERK1 : P-ERK2 ratio. We
have shown that ERK1−/− hepatocytes proliferate with
similar kinetics as wild-type hepatocytes after in vivo PHT
and in vitro [94]. At the contrary, silencing ERK2 has a
strong impact on cell proliferation [66, 94]. These results
are in accordance with several papers listed above that place
ERK2 as a positive regulator of cell proliferation. We went
further in the analysis of putative roles of ERK1 and ERK2 in
hepatic processes and established a link between ERK1 and
the cell survival of hepatocytes. Indeed, silencing ERK1 using
RNAi decreases susceptibility to apoptosis as it is observed in
ERK1-deﬁcient hepatocytes. This is in accordance with the
report from Bourcier et al. which has shown that ERK1−/−
keratinocytes are resistant to apoptosis induced by different
agents or stress [95]. Interestingly inhibiting ERK2 did not
reach this effect. But this is probably not so simple and
associating one isoform to the regulation of one speciﬁc
cellular function could be a dangerous shortcut. As an
example, in ovarian cells, the silencing of ERK1 triggers
the opposite phenotype to that observed in hepatocytes
since cells become more sensitive to apoptosis [96]. How
the inhibition of the same protein could have radically
opposite effects? The localization of the isoforms inside the
cell could be a response element. In that sense, MEK1 and
MEK2 were proposed to regulate distinct cellular functions
in hepatocytes by localizing ERK2 to different regions of the
cell [97]. Following activation by MEK1, ERK2 translocates
to the nucleus where it would trigger a proliferative response.
At the opposite, when activated by MEK2, ERK2 retains
a cytoplasmic localization to mediate survival. This could
explain why one isoform would regulate distinct functions
according to the cell type.
Finally and in order to reconcile all these data, one can
easily imagine that ERK1 and ERK2 regulate overlapping
fundamental functions with regard to the most fundamental
processes such as proliferation in nonspecialized cells. Results
obtained on MEFs cells and which explicit a dose-response
effect of ERK on the intensity of cell proliferation argue
in that sense [98]. Interestingly, all the major differences
that were observed between ERK isoforms have been made
on more differentiated cells, and notably hepatocytes. This
could suggest a specialization of ERK1 and ERK2 in the
regulation of unique biological functions in differentiated
cells. ERK1 and ERK2 also share dozen of substrates so one
could speculate that potential differences in substrate affinity
could explain the predominant role of one isoform in a
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function due to the presence of a particular set of partners,
in other words in a particular cellular context.
6. Roles of theMEK1/2-ERK1/2 Pathway in
Hepatocellular Carcinoma
The MEK/ERK signaling pathway plays a central role in
the regulation of various physiological processes such as
proliferation, survival or cell motility. Thus, its disregulation
has often been associated with the promotion or develop-
ment of tumor cell growth. Indeed, the chemical inhibition
of MEK1/2 kinase activities blocks in vitro as well as in
vivo proliferation of a variety of tumor models, including
hepatocellular carcinoma (HCC) [99–103]. Moreover, active
mutant forms of Raf or MEK have been shown to transform
different cell types [90, 104–106]. The best illustration
of MAPK pathway importance in oncogenesis lies in the
observation of an ERK1/2 overactivation in 50 out of
138 human tumor cell lines [107]. Indeed, an increased
expression and activation of the MEK1/2, and ERK1/2
kinases has been reported in human and mice primary liver
tumors [108–111]. Active forms of the MEK/ERK pathway
components including pRAF1, pMEK1/2 and pERK1/2 were
also associated with poor prognosis in patients with HCC
[112, 113]. However, in HCC, the overactivation of the
MEK/ERK pathway did not result (or rarely) from an
activating mutation of an upstream protein, namely, the
GTPase Ras or the Raf protein kinase. Generally, the protein
Ras is foundmutated in about 30% of all human cancers with
a high prevalence in the pancreas (90%) and colon (50%)
adenocarcinomas [114]. The BRAFV600Emutation is on the
other hand found in about 20% of tumors and especially in
melanoma (∼ 50%) [115]. InHCC, Ras and BRAFmutations
are rare in humans or could be related to some etiologic
factors or genetic backgrounds [116–119]. Overactivation
of the MEK/ERK pathway is rather a consequence of a
disinhibition, an upregulation of upstream activators, or an
oncogenic stimulation.
For example, Calvisi et al. have shown from 80 surgical
resections of HCC that 100% of tested malignant tissues had
a constitutive activation of Ras and this was linked to the
loss or reduction of the Ras inhibitory proteins NORE1A
and RASSF1A [120]. Different inhibitors of the MEK/ERK
pathway like RKIP, Sprouty-2, Spred-1, or Spred-2 are also
frequently downregulated in human tissues of HCC. These
decreases, or losses of activity, are supposed to have an
important impact on HCC development and progression
since ectopic expression of these different inhibitors is
sufficient to inhibit the MAPK pathway but, most of all,
to suppress tumor cell proliferation both in vitro and in
vivo [121–124]. The downregulation of the previously cited
inhibitors would provide an increased activation of the
kinases ERK1/2. Moreover, in poor prognosis HCC, ERK1/2
activity should also be unrestrained given the weakened
expression of theMAPK phosphatase DUSP-1 found in those
patients [125].
In addition, the ERK1/2 kinases could also undergo
a more intense stimulation through the overexpression of
various components of the MEK/ERK pathway. For instance,
the protein c-Raf could be an important source of ERK
overactivation. Indeed, Hwang and colleagues have shown
that the c-Raf kinase is upregulated in almost all cirrhosis
and tumor tissues analyzed. A signiﬁcantly higher level
of expression of c-Raf was also reported in hepatocellular
carcinomas when compared to cirrhosis [126]. Numerous
tyrosine kinase receptors and their ligands also accuse an
increased expression in HCC [127]. The signaling via these
receptors will thus activate the MAPK pathway cascade and
lead to a sustained activation of ERK1/2. For example, the
EGF receptor is overexpressed in about 40% to 70% of HCC
[128–130]. Importantly, the transforming growth factor-α
which is one of the EGFR ligands presents in parallel an
increased expression in cirrhosis and early HCC. Since
the gene encoding for TGF-α is also a target of the Ras
pathway, an autoampliﬁcation loop could be established
ensuring, by the way, a persistent activation of the MEK/ERK
pathway [131–133]. Hepatocellular carcinoma is also one
of the most vascularized solid tumors links to a strong
angiogenesis. Therefore, it is not surprising to ﬁnd an
upregulation of various proangiogenic factors such as VEGF,
its receptor VEGFR, or the PDGF. All of these proteins
will provide activator signals for the MEK/ERK pathway
[134–136]. In HCC, a signiﬁcant deregulation of the IGF
signaling has also been reported, and notably a signiﬁcant
increase in IGF2 bioavailability. This was mediated by the
upregulation of IGF2 via epigenetic mechanisms and by
the downregulation of the IGF2R receptor, which normally
lead to the lysosomal degradation of IGFs [79, 137, 138].
In addition, an overexpression of c-MET is observed in
approximately 50% of HCC and this was associated with
poor prognosis [139].
Finally, ERK1/2 overactivation in HCC could be due
to Hepatitis-B virus (HBV) or C virus (HCV) infections,
the two major etiologic factors of primary liver cancers.
Indeed HCV carrier patients have higher rates of pERK1/2
than other HCC patients [113]. Thus, the core protein
and the envelope protein E2 of the HCV and the HBX
protein and preS2-activator large surface protein of HBV
have been shown to directly activate the MEK/ERK pathway
but by different mechanisms [140–144]. For instance, the
HBX protein could upregulate the EGFR and interacts with
the protein PIN1 to facilitate the dephosphorylation of c-
Raf while activation by the preS2-activator large surface
protein used PKC-dependent mechanisms [142, 143, 145,
146]. The envelope protein E2 of HCV stimulates the
MEK/ERK pathway by binding to the CD81 receptor or
to the low density lipoprotein receptor (LDLR). Anyway,
MEK/ERK activation by viruses is postulated to promote
hepatocarcinogenesis by facilitating the proliferation and
survival of infected cells [147].
The MEK/ERK overactivation in hepatocarcinoma cells
will promote various cellular processes. First, the prolif-
eration of neoplastic cells would be obviously improved.
Indeed, MEK1/2 inhibition, conducted by the use of different
chemical inhibitors, could abolish the in vitro proliferation
of numerous human and rat hepatocarcinoma cell lines.
Growth of xenograft tumors in mice is also severely impaired
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in a context of MEK/ERK inhibition [94, 99, 104, 111,
148–152]. Using RNAi, we have speciﬁed the molecular
mechanism involved in tumor hepatocyte proliferation. We
have shown that MEK1 deﬁciency suppressed both in vitro
and in vivo proliferation of Huh7 cells. On the other side,
MEK2 silencing did not affect the proliferation capacity
of transformed cells [151]. Similar to normal hepatocytes,
tumor growth is also supported by the kinase ERK2 but
not by ERK1. Indeed, ERK2 targeting by stable chemically
modiﬁed siRNA altered the in vitro proliferation as well as
the in vivo growth of the highly tumorigenic F1 cells. We have
also demonstrated that ERK2 was primordial for the in vivo
proliferation of the Huh-7 cell line [99, 151]. Interestingly, it
is noteworthy that hepatoma cells exhibit a higher expression
of ERK2 than ERK1 while normal hepatocytes have a more
balanced ERK1 : ERK2 ratio. This could reﬂect the difference
of functions carried by these kinases in the particular
context of liver. Indeed, we showed that ERK2 favored
the proliferation of normal and transformed hepatocytes
as opposed to ERK1 which could promote a death signal
[66] (Guegan, personal data). Given the permanent and
sustained MEK/ERK activation in HCC, one could speculate
that the newly transformed hepatocyte should thus prime
ERK2 functions while diminishing ERK1 prodeath activity.
Moreover and besides its role in cell proliferation, we
have shown that ERK2 but not ERK1 was involved in
hepatoma cell motility and invasiveness by an uPAR and
P70S6K dependent mechanism. RNAi-mediated inhibition
of ERK2 or P70S6K led to strongly reduced cell motility
[153]. However, this is not the unique mechanism by which
the MAPK pathway regulates HCC invasion. Indeed Honma
et al. have shown that an active mutant form of MEK1 could
suppress the E-cadherin mediated homotypic adhesion and
thus potentiate cell migration [154]. ERK1/2 activity was
also involved in the migration of three metastatic HCC cell
lines but in a PKC-β dependent mechanism. Interestingly,
ERK activation status was shown to increase following the
metastatic potential of the cell lines analyzed [155]. Hence,
the MEK/ERK overactivation found in tumor cell could
support the HCC progression and metastasis.
Finally, this overactivation could also promote the
survival of transformed hepatocytes. Indeed it has been
shown that treatment of HepG2 or Hep3B cells by MEK1/2
inhibitors led to an apoptosis engagement [111]. Inhibition
of MEK1/2 could also sensitize hepatoma cells to the death
induced by ER-stress [156]. Moreover, active form of MEK1
prevented serum deprivation-induced death of hepatocar-
cinoma cells [157] and in HepG2, MEK/ERK activity has
been reported to contribute to cisplatin induced death [158].
The MEK/ERK pathway has also been shown to protect
transformed hepatocytes from TGF-β-induced apoptosis, a
natural inducer of apoptosis in hepatocytes, produced in the
liver by hepatic stellate cells [159]. The escape from TGF-β
suppressive effects is an important step in hepatocarcinogen-
esis. Liver tumor bearing late TGF-β gene signature is indeed
more aggressive than those expressing early gene signature
[160]. Hence the MEK/ERK overactivation might play an
important role in the initiation or development of HCC.
The prosurvival effects of the MEK/ERK pathway in tumor
cells have been shown to pass through the upregulation or
stimulation of different antiapoptotic factors such as Bcl-
2, Bim, or Bad (for review see [161]). For instance, it has
been shown in hepatocarcinoma cells that ERK1/2 could
phosphorylate the antiapoptotic factor Mcl-1 on thr163 in
order to stabilize it and to thus enhance its prosurvival
function [162].
The critical involvement of the MEK/ERK pathway
in HCC tumorigenesis strongly suggests that the kinases
MEK1/2 or ERK1/2 could be promising therapeutic targets.
Sorafenib advent in therapy has also clearly demonstrated
the potential of targeting signaling pathways in HCC. Given
the predominant role of ERK2 in transformed hepatocyte
proliferation, survival, and motility and given the prodeath
role of ERK1, it could be preferential to speciﬁcally target
ERK2 without affecting ERK1 activity. By this way, this might
have different effects compared to a nonspeciﬁc chemical
inhibition of both kinases, what could ultimately improve
therapeutic beneﬁts.
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